Another hope for multiple sclerosis patients. Improved Interferon-beta patent recently granted byAugust 06, 2003Blurred vision, weak limbs, tingling sensations, unsteadiness and fa-tigue are the symptoms of one of the most common diseases of the central nervous system, the multiple sclerosis (MS). It is estimated that MS currently affects over 2,500,000 people worldwide. There is new hope for MS patients: The protein Interferon-beta, which is produced in bacterial or mammalian cells by genetic engineering, is being used successfully in the treatment of multiple sclerosis. However, the very high hydrophobicity and thus poor solubility of Interferon-beta, proves to be problematic for the production and clinical efficacy of recombinant human Interferon-beta. In order to solve this problem, scientists from the German Fraunhofer Institute for Interfacial Engineering and Biotechnology (Fraunhofer-Institut für Grenzfl'¤chen- und Bioverfahrenstechnik IGB) designed variants of recombinant human Interferon-beta whose solubility is improved. They replaced the hydrophobic portions of the molecule by soluble ones. This technique is known as hydrophobicity engineering. »Our goal was to reduce clustering between the molecules in order to increase the protein yield and thus pharmacological effectiveness«, says Professor Bernd Otto. »Moreover, the improved hydrophilicity of these modified proteins simplifies their manufacture, transportation, storage and application as a medicinal drug«, Otto specifies further advantages of the improved Interferon-beta. The researchers' success becomes outstanding on a global level, as in June 2003 the US Patent and Trademark Office granted a patent on recombinant human beta-interferon with enhanced solubility (United States Patent 6,572,853) caused by the substitution of nine amino acids on its surface. Additionally, the European Patent Office just announced its willingness to grant a patent for the whole of the European states, the German patent has already been granted. The patented variant has been expressed and purified from bacterial (E. coli) as well as mammalian (CHO) cells. In both cases, the variant shows a highly increased pharmacokinetic stability and bioavailability when investigated in animal experiments. For clinical studies, therefore, there is the hope of fewer side-effects and enhanced effectiveness in the therapy of MS. Furthermore, the soluble Interferon-beta will also be suitable for the therapy of other viral and oncological indications. Negotiations with pharmaceutical companies will be intensified. Fraunhofer Institut - Grenzflächen- und Bioverfahrenstechnik (IGB) |
|||||||||||||||||||||
| Related Multiple Sclerosis Current Events and Multiple Sclerosis News Articles Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." Factors from common human bacteria may trigger multiple sclerosis Current research suggests that a common oral bacterium may exacerbate autoimmune disease. The related report by Nichols et al, "Unique Lipids from a Common Human Bacterium Represent a New Class of TLR2 Ligands Capable of Enhancing Autoimmunity," appears in the December 2009 issue of The American Journal of Pathology. Drug studied as possible treatment for spinal injuries Researchers have shown how an experimental drug might restore the function of nerves damaged in spinal cord injuries by preventing short circuits caused when tiny "potassium channels" in the fibers are exposed. CSHL team solves structure of NMDA receptor unit that could be drug target for neurological diseases A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses. Men leave: Separation and divorce far more common when the wife is the patient A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact. Neurologists Investigate Possible New Underlying Cause of MS Neurologists at the University at Buffalo are beginning a research study that could overturn the prevailing wisdom on the cause of multiple sclerosis (MS). Scientists demonstrate link between genetic defect and brain changes in schizophrenia Researchers at the University of North Carolina at Chapel Hill School of Medicine have found that the 22q11 gene deletion - a mutation that confers the highest known genetic risk for schizophrenia - is associated with changes in the development of the brain that ultimately affect how its circuit elements are assembled. Gentle touch may aid multiple sclerosis patients While gripping, lifting or manipulating an object such as drinking from a cup or placing a book on a shelf is usually easy for most, it can be challenging for those with neurological diseases such as multiple sclerosis or Parkinson's, or for people who had a stroke. For them, the tight gripping can cause fatigue, making everyday tasks difficult. Urate in blood and spinal fluid may predict slower decline in patients with Parkinson's disease Higher concentration of urate (an antioxidant) in the blood and spinal fluid of patients with early Parkinson's disease is associated with slower rates of clinical decline. Oxidized form of a common vitamin may bring relief for ulcerative colitis New research published in the Journal of Leukocyte Biology finds retinoic acid may alleviate ulcerative colitis and similar irritable bowel diseases. More Multiple Sclerosis Current Events and Multiple Sclerosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||